Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


Pharma M&A is on the way

Posted 15 September 2020

Pharmacuetical companies should expect a flurry of mergers and acquisitions (M&A) as they brace themselves to withstand the shocks induced by COVID-19 and forge a strong recovery for the next new normal, according to new research from McKinsey & Company.

While the industry is working at a blistering pace to develop COVID-19 vaccines and treatments, the pandemic-forced digitisation of healthcare is unlikely to unwind even if medical solutions are found.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Approvals Action
Two new neuro drugs
Seizures, Parkinson's drugs registered
Special Report
Aust Covid Vaccine Tracker
Live updates on frontrunners, local trials and deals
Top of the Hill
Value in a post-Covid world
Time to reconsider what Aussies really want